It has shown dramatic therapeutic effects, both alone and in combination, for the treatment of breast cancer, including reduction of trastuzumab-refractory risk and use in combination with capecitabine for the treatment of advanced HER2 + breast cancer (Geyer et al., 2006; Nahta et al., 2007). This evidence concerns the gene ERBB2 and breast cancer.